On February 24, 2025 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), reported the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025 (Press release, Crinetics Pharmaceuticals, FEB 24, 2025, View Source [SID1234650469]). Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Toby’s deep finance experience in commercial-stage global pharmaceutical companies and emerging biotech is essential as we prepare for our first commercial launch and advance numerous promising candidates through development. I would also like to thank Marc Wilson for his invaluable leadership and financial stewardship during his tenure, guiding the company through critical phases of growth."
"I am honored to join Crinetics at such a pivotal time in the company’s journey and am deeply inspired by its mission to improve the lives of people living with endocrine-related conditions," said Mr. Schilke. "I look forward to collaborating with the Crinetics team and stakeholders to accelerate our growth objectives and create long-term value."
Prior to joining Crinetics, Mr. Schilke served as chief financial officer at Revance Therapeutics, where he oversaw finance, investor relations, IT, and technical operations for a public company with 650 employees, supporting the transformation to a commercial company with two product launches and over $700 million in cumulative revenue. Previously, Mr. Schilke served as Chief Financial Officer at Achaogen, where he built out the financial planning and analysis, accounting, procurement, information technology, and facilities management functions to support the approval and launch of the company’s first product. In these roles, Mr. Schilke successfully executed over $1.5 billion in equity, convertible debt, and structured debt financing, while also leading numerous partnerships and M&A deals. Earlier in his career, he spent more than a decade in increasing roles of responsibility at Roche/Genentech in corporate development, commercial finance, marketing and global operations. Mr. Schilke holds a bachelor’s degree in chemical engineering from Lafayette College, a master’s degree in chemical engineering from the University of California, Berkeley, and a master’s degree in business administration from Cornell University.
On March 10, 2025, the Company expects to grant Mr. Schilke 52,000 restricted stock units (RSUs) and a stock option to purchase 80,000 shares of common stock under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the "2021 Inducement Plan"). The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee’s continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant. The RSUs and stock option will be granted as an inducement material to Mr. Schilke entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).